2026-2034年全球局部用药研发产机构（CDMO）市场规模、份额、趋势及成长分析报告

预计到 2034 年，局部用药 CDMO 市场规模将从 2025 年的 591 亿美元成长至 1,514.1 亿美元，2026 年至 2034 年的复合年增长率为 11.02%。

由于药品研发和生产活动外包的趋势日益明显，全球外用药物CDMO市场正稳定成长。 CDMO为乳霜、凝胶、软膏和经皮贴剂等製剂提供配方、生产和包装服务。对皮肤病治疗和疼痛管理的需求不断增长，推动了市场扩张。製药公司越来越依赖CDMO来降低成本并缩短产品上市时间。

关键成长要素包括皮肤疾病盛行率的上升和对个人化医疗日益增长的需求。合约研发生产机构 (CDMO) 提供专业的技术专长、合规性保障和可扩展的生产能力。药物递送技术的进步正在提高产品的疗效和稳定性。此外，对非专利外用药物的需求不断增长，也促进了外包业务的发展。

展望未来，不断扩充的药物研发管线和不断增加的研发投入预计将对市场产生正面影响。新兴市场医疗保健产业尚处于发展阶段，将涌现新的外包机会。各公司正致力于先进的製剂技术和永续的生产方式。随着製药公司将效率和创新置于优先地位，全球外用药物CDMO市场预计将持续保持长期成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球外用药物CDMO市场：依产品类型划分

• 市场分析、洞察与预测
• 半固态製剂（乳膏、软膏、凝胶和其他半固态製剂）
• 液体
• 经皮吸收产品
• 固态剂型

第五章 全球局部用药研发与生产机构（CDMO）市场：依治疗领域划分

• 市场分析、洞察与预测
• 皮肤科
• 疼痛管理
• 创伤护理
• 眼科
• 其他治疗领域

第六章 全球外用药物CDMO市场：依服务类型划分

• 市场分析、洞察与预测
• 契约製造
• 合约开发

第七章 全球外用药物CDMO市场：依最终用途划分

• 市场分析、洞察与预测
• 製药公司
• 生技公司
• 其他最终用户

第八章 全球外用药物CDMO市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Ascendia Pharmaceuticals
  • Bora Pharmaceuticals
  • Cambrex
  • Contract Pharmaceuticals
  • DPT Laboratories
  • MedPharm
  • PCI Pharma Services
  • Pierre Fabre Group
  • Piramal Pharma Solutions
  • The Lubrizol

The Topical Drugs CDMO Market size is expected to reach USD 151.41 Billion in 2034 from USD 59.10 Billion (2025) growing at a CAGR of 11.02% during 2026-2034.

The Global Topical Drugs CDMO Market is growing steadily due to increasing outsourcing of drug development and manufacturing activities. Contract Development and Manufacturing Organizations (CDMOs) provide formulation, production, and packaging services for creams, gels, ointments, and transdermal patches. Rising demand for dermatological and pain management treatments is supporting market expansion. Pharmaceutical companies are increasingly relying on CDMOs to reduce costs and accelerate time-to-market.

Key growth drivers include the increasing prevalence of skin disorders and growing demand for personalized medicine. CDMOs offer specialized expertise, regulatory compliance, and scalable manufacturing capabilities. Advancements in topical drug delivery technologies are improving product effectiveness and stability. Additionally, rising demand for generic topical medications is strengthening outsourcing activities.

Looking ahead, the market is expected to benefit from expanding pharmaceutical pipelines and increased R&D investments. Emerging markets with developing healthcare industries will create new outsourcing opportunities. Companies are focusing on advanced formulation technologies and sustainable manufacturing practices. As pharmaceutical firms prioritize efficiency and innovation, the Global Topical Drugs CDMO Market is projected to experience consistent long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Semi-Solid Formulations (Creams, Ointments, Gels, Other Semi-Solid Formulations)
• Liquid Formulations
• Transdermal Products
• Solid Formulations

By Therapeutic Area

• Dermatology
• Pain management
• Wound care
• Ophthalmology
• Other therapeutic areas

By Service Type

• Contract manufacturing
• Contract development

By End Use

• Pharmaceutical Companies
• Biotechnology Companies
• Other End Users

COMPANIES PROFILED

• Ascendia Pharmaceuticals, Bora Pharmaceuticals, Cambrex, Contract Pharmaceuticals, DPT Laboratories, MedPharm, PCI Pharma Services, Pierre Fabre Group, Piramal Pharma Solutions, The Lubrizol
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TOPICAL DRUGS CDMO MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Semi-Solid Formulations (Creams, Ointments, Gels, Other Semi-Solid Formulations) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Liquid Formulations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Transdermal Products Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Solid Formulations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TOPICAL DRUGS CDMO MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Pain management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Wound care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other therapeutic areas Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TOPICAL DRUGS CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Service Type
• 6.2. Contract manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Contract development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TOPICAL DRUGS CDMO MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL TOPICAL DRUGS CDMO MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product Type
  • 8.2.2 By Therapeutic Area
  • 8.2.3 By Service Type
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product Type
  • 8.3.2 By Therapeutic Area
  • 8.3.3 By Service Type
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product Type
  • 8.4.2 By Therapeutic Area
  • 8.4.3 By Service Type
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product Type
  • 8.5.2 By Therapeutic Area
  • 8.5.3 By Service Type
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product Type
  • 8.6.2 By Therapeutic Area
  • 8.6.3 By Service Type
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL TOPICAL DRUGS CDMO INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Ascendia Pharmaceuticals
  • 10.2.2 Bora Pharmaceuticals
  • 10.2.3 Cambrex
  • 10.2.4 Contract Pharmaceuticals
  • 10.2.5 DPT Laboratories
  • 10.2.6 MedPharm
  • 10.2.7 PCI Pharma Services
  • 10.2.8 Pierre Fabre Group
  • 10.2.9 Piramal Pharma Solutions
  • 10.2.10 The Lubrizol